Gastrointestinal Tolerance Clinical Trial
Official title:
Gastrointestinal Tolerance and Acceptability of a High Protein, High Calorie Pudding in Adult Patients With/or at Risk for Malnutrition
NCT number | NCT04945083 |
Other study ID # | BL55 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 13, 2021 |
Est. completion date | December 9, 2021 |
Verified date | January 2022 |
Source | Abbott Nutrition |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multi-center, prospective, non-randomized, non-blinded, single-arm, single treatment study to evaluate the tolerance of a nutritional pudding.
Status | Completed |
Enrollment | 25 |
Est. completion date | December 9, 2021 |
Est. primary completion date | December 9, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subject has voluntarily signed and dated an ICF approved by an IEC, and provided applicable privacy authorization prior to any participation - Subject is considered by a dietitian or clinician as malnourished or at risk for malnutrition based on current use of an oral nutritional supplement (ONS), recently identified as malnourished or at risk of malnutrition based on validated malnutrition screening tool or has had weight loss within last two months as a result of a hospitalization or chronic illness - Subject currently has normal GI function - Subject requires ONS and is willing to comply with the study protocol Exclusion Criteria: - Subject has severe dementia or delirium, eating disorder, history of significant neurological or psychiatric disorder affecting abilities to answer questions, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures - Subject had a history of diabetes as evidenced by taking antihyperglycemic medications or by self-reported dietary modification - Subject is currently taking or has taken antibiotics within 1 week prior to enrollment - Subject has undergone major GI surgery less than 3 months prior to enrollment in the study - Subject has current active malignant disease or was treated within the last 6 months for cancer, except basal or squamous cell skin carcinoma, prior to enrollment - Subject has an immunodeficiency disorder - Subject has had a myocardial infarction within the last 3 months prior to enrollment - Subject is known to be allergic or intolerant to any ingredient found in the study product - Subject has an aversion to any of the flavours of product being tested - Subject has an obstruction of the GI tract precluding ingestion or absorption of the study product, inflammatory bowel disease, gastric esophageal reflux disease, short bowel syndrome, or other major gastrointestinal disease-causing symptoms including (but not limited to) uncontrollable severe diarrhea, nausea, or vomiting - Subject is currently taking medications/dietary supplements/substances that could profoundly modulate metabolism or affect gastrointestinal motility - Participation in another study that has not been approved as a concomitant study - Subject has a clinical condition that is contraindicated with this product as determined by the clinician in accordance with standard of care - Subject is pregnant |
Country | Name | City | State |
---|---|---|---|
United Kingdom | North Coast Medical Ltd, Newquay Health Centre | Newquay | Cornwall |
United Kingdom | Morrab Surgery | Penzance | Cornwall |
United Kingdom | The Alverton Practice, Atlantic Medical | Penzance | Cornwall |
Lead Sponsor | Collaborator |
---|---|
Abbott Nutrition |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Weight | For BMI Calculation | Baseline to Study Day 28 | |
Other | Height | For BMI Calculation | Baseline to Study Day 28 | |
Other | Medication Usage | Subject reported medication usage | Baseline to Study Day 28 | |
Other | Adverse Events | Subject reported adverse events | Baseline to Study Day 28 | |
Primary | Gastro-Intestinal Tolerance | Subject completed Bristol Stool Type questionnaire; Stool is classified into 7 groups (Types 1-7) with Type 3-4 as ideal stools | Study Day 1 to Study Day 8 | |
Secondary | Nutritional Supplement Palatability | Subject completed questionnaire; 4 questions scaled from 1 -Dislike Extremely to 9-Like Extremely; 2 questions scaled from Not at all Enough to Far Too | Study Day 1 to Study Day 8 | |
Secondary | Nutritional Supplement Compliance | Subject completed daily intake questionnaire including amount of serving consumed | Study Day 1 to Study Day 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04100460 -
A Double Blind Study on the Gastrointestinal Effects of Arabinoxylan (Leaf Fiber Extract).
|
N/A | |
Completed |
NCT00977964 -
Tolerance of Healthy Term Infants Fed Infant Formulas #3
|
Phase 3 | |
Not yet recruiting |
NCT05827198 -
Evaluating the Impact of Incremental Doses of a Sugar Replacer Blend on Gastrointestinal Tolerance in Candies
|
N/A | |
Completed |
NCT03945149 -
A Clinical Trial to Evaluate the Chronic Safety and Tolerance of Turmipure Gold™ in Healthy Subjects
|
N/A | |
Completed |
NCT05369494 -
Infants Fed a Hydrolyzed Infant Formula
|
N/A | |
Completed |
NCT03539146 -
Gastrointestinal Tolerance, Satiation and Sensory Acceptance of Yogurts Containing Dietary Fiber and Coffee Cascara Extract
|
N/A | |
Completed |
NCT02757924 -
Behavior of Infants Fed Formula Supplemented With Prebiotics
|
N/A | |
Completed |
NCT05213494 -
The Effects of Soluble Corn Fiber on Gastrointestinal Tolerance and Fecal Microbiome in Healthy Children
|
N/A | |
Completed |
NCT05051202 -
A Study Assessing the Tolerable Upper Intake Level and Safety of Sugars From Fiber
|
N/A | |
Completed |
NCT01902212 -
Evaluation of an Oral Nutrition Supplement
|
N/A | |
Completed |
NCT03597113 -
Evaluation of Infants Fed an Extensively Hydrolyzed Hypo Allergenic Infant Formula
|
||
Completed |
NCT04745455 -
Gastrointestinal Tolerance and Safety of an Infant Formula Containing Prebiotics, Probiotics and Postbiotics.
|
N/A | |
Completed |
NCT02322138 -
Gastrointestinal Tolerance of Infant Formula
|
N/A | |
Completed |
NCT03648255 -
TolerUp Enteral Feeding Protocol
|
||
Completed |
NCT03769012 -
Ability of Beta-glucan Supplementation to Augment Immune Function
|
N/A | |
Completed |
NCT02456831 -
Soy Formula Feedings in Healthy, Term Infants
|
N/A | |
Completed |
NCT03628183 -
Tolerance of Infants Fed a Hydrolysate Formula
|
N/A | |
Completed |
NCT02456805 -
Alternate Formula Feedings in Formula Intolerant Infants
|
N/A | |
Recruiting |
NCT04966299 -
Effect of Daily Erythritol Versus Sucrose Intake Over 5 Weeks on Glucose Tolerance in Adolescents
|
N/A | |
Completed |
NCT02746016 -
Effect of Formula on Infant Behavior
|
N/A |